This suggests that AnxA6 levels in EVs from molecularly distinct breast cancer subtypes and/or chemotherapy-treated patients may be useful to predict the risk of metastasis [96,97] especially in patients who do not achieve a complete pathological response. Here, ANXA6 is linked to breast carcinoma.